STEELHEAD PARTNERS LLC
13F filer · CIK 1133521 · Seattle, WA
Summary
STEELHEAD PARTNERS LLC reported $1.40B across 25 positions in its 13F for 2026 Q2, filed Aug 14, 2026. The largest holdings are Uber Technologies Inc (10.3%), Bridgebio Pharma Inc (8.9%), Akamai Technologies Inc (8.6%). Versus 2026 Q1, leaving options aside, it opened 8 new positions, added to 10, trimmed 2 and sold out of 7.
Reported value$1.40B
Positions25
Report period2026 Q2
FiledAug 14, 2026
New positions8
Added10
Trimmed2
Sold out7
Top 25 holdings
By reported value, options listed separately · change vs 2026 Q1
Uber Technologies IncNo ticker matchAdd
Weight 10.3%Value $143.91MPrincipal $120.00M +20.00%
Bridgebio Pharma IncNo ticker matchHold
Weight 8.9%Value $124.78MPrincipal $70.00M
Akamai Technologies IncNo ticker matchAdd
Weight 8.6%Value $120.16MPrincipal $100.00M +150.00%
Alarm Com Hldgs IncNo ticker matchHold
Weight 6.1%Value $85.53MPrincipal $90.00M
Weight 5.6%Value $79.14MPrincipal $70.50M +2.17%
Weight 5.6%Value $78.16MPrincipal $65.00M +8.33%
Dexcom IncNo ticker matchHold
Weight 5.5%Value $77.48MPrincipal $82.85M
Nutanix IncNo ticker matchHold
Weight 5.2%Value $73.51MPrincipal $65.00M
Weight 4.6%Value $64.44MPrincipal $50.00M -28.57%
Weight 4.1%Value $57.56MPrincipal $59.14M +47.85%
Weight 4.1%Value $57.30MPrincipal $61.00M +6.09%
Weight 3.5%Value $48.57MPrincipal $40.23M
Weight 3.1%Value $43.29MPrincipal $50.00M +49.25%
Weight 3.0%Value $42.59MPrincipal $30.00M
Irhythm Holdings IncNo ticker matchAdd
Weight 3.0%Value $42.11MPrincipal $38.12M +5.54%
Post Hldgs IncNo ticker matchAdd
Weight 2.8%Value $39.47MPrincipal $38.01M +30.12%
Halozyme Therapeutics IncNo ticker matchAdd
Weight 2.8%Value $39.05MPrincipal $35.00M +83.70%
Weight 2.5%Value $34.40MPrincipal $35.00M
Weight 2.4%Value $33.29MPrincipal $20.00M
Weight 2.0%Value $28.36MPrincipal $10.00M -56.52%
Weight 1.8%Value $25.85MPrincipal $28.00M
Weight 1.7%Value $23.14MPrincipal $20.43M
Weight 1.5%Value $20.57MPrice $283.30Shares 55KSince Jun 30 -24.02%
Travere Therapeutics IncNo ticker matchNew
Weight 1.3%Value $17.69MPrincipal $15.00M
Weight 0.1%Value $1.89MPrice $19.29Shares 129KSince Jun 30 +32.21%
| Stock | Weight | Value | Since Jun 30 | Shares change | Action |
|---|---|---|---|---|---|
| Uber Technologies IncNo ticker match | 10.3% | $143.91M | — | +20.00% | Add |
| Bridgebio Pharma IncNo ticker match | 8.9% | $124.78M | — | — | Hold |
| Akamai Technologies IncNo ticker match | 8.6% | $120.16M | — | +150.00% | Add |
| Alarm Com Hldgs IncNo ticker match | 6.1% | $85.53M | — | — | Hold |
| 5.6% | $79.14M | — | +2.17% | Add | |
| 5.6% | $78.16M | — | +8.33% | Add | |
| Dexcom IncNo ticker match | 5.5% | $77.48M | — | — | Hold |
| Nutanix IncNo ticker match | 5.2% | $73.51M | — | — | Hold |
| 4.6% | $64.44M | — | -28.57% | Trim | |
| 4.1% | $57.56M | — | +47.85% | Add | |
| 4.1% | $57.30M | — | +6.09% | Add | |
| 3.5% | $48.57M | — | — | New | |
| 3.1% | $43.29M | — | +49.25% | Add | |
| 3.0% | $42.59M | — | — | New | |
| Irhythm Holdings IncNo ticker match | 3.0% | $42.11M | — | +5.54% | Add |
| Post Hldgs IncNo ticker match | 2.8% | $39.47M | — | +30.12% | Add |
| Halozyme Therapeutics IncNo ticker match | 2.8% | $39.05M | — | +83.70% | Add |
| 2.5% | $34.40M | — | — | New | |
| 2.4% | $33.29M | — | — | New | |
| 2.0% | $28.36M | — | -56.52% | Trim | |
| 1.8% | $25.85M | — | — | Hold | |
| 1.7% | $23.14M | — | — | New | |
| 1.5% | $20.57M | -24.02% | — | New | |
| Travere Therapeutics IncNo ticker match | 1.3% | $17.69M | — | — | New |
| 0.1% | $1.89M | +32.21% | — | New |
Weight is the share of the reported 13F value, including options at notional value. “Since Jun 30” compares the latest close with the quarter-end price implied by the filing (value ÷ shares).
Largest buys in 2026 Q2
Akamai Technologies IncNo ticker match≈ $72.10MAdd
Largest sells in 2026 Q2
AEIS 2 1/2 09/15/28No ticker match≈ $97.50MSold
AKAM 1 1/8 02/15/29No ticker match≈ $87.99MSold
ITRI 1 3/8 07/15/30No ticker match≈ $35.35MSold
Source: SEC Form 13F, values as reported by the filer. Filings lag up to 45 days after quarter end and cover only certain long positions. Research only, not investment advice.